Brief: Reviva Pharmaceuticals Announces Update On Recover, A Pivotal Phase 3 Global Study Evaluating Brilaroxazine For Treatment Of Schizophrenia

Reviva Pharmaceuticals Holdings

03/05/2022 12:37

May 3 (Reuters) - Reviva Pharmaceuticals Holdings, Inc.
 RVPH.O :
    * REVIVA PHARMACEUTICALS ANNOUNCES UPDATE ON RECOVER, A
PIVOTAL
PHASE 3 GLOBAL STUDY EVALUATING BRILAROXAZINE FOR TREATMENT OF
SCHIZOPHRENIA
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - ANNOUNCED THAT
RECOVER
STUDY IS PROGRESSING WELL AND ALL SITES IN UNITED STATES (U.S.)
HAVE BEEN INITIATED
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - GLOBAL SITES IN
EUROPE
AND INDIA REMAIN ON TRACK TO INITIATE IN MID-2022
    * REVIVA PHARMACEUTICALS- PHASE 3 RECOVER STUDY CONTINUES TO
PROGRESS WELL, WITH BRILAROXAZINE DEMONSTRATING SAFE AND WELL
TOLERATED PROFILE
    * REVIVA PHARMACEUTICALS- LOOK FORWARD TO SHARING FURTHER
UPDATES
ON ENROLLMENT IN SECOND HALF OF 2022 & ANTICIPATE PROVIDING
TOPLINE DATA IN MID-2023

Source text for Eikon:  ID:nGNX6s7S98 
Further company coverage:  RVPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))